When Injection Site Reactions on Mounjaro (Tirzepatide) Become a Reason to Stop

What does the Mounjaro label say to stop for?

The hypersensitivity section of the Mounjaro prescribing information states that serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with the drug. If a hypersensitivity reaction occurs, the label says to discontinue Mounjaro, treat promptly per standard of care, and monitor until signs and symptoms resolve [1]. The label also says not to use Mounjaro in anyone with a previous serious hypersensitivity reaction to tirzepatide or to any of its excipients, and lists known serious hypersensitivity as a contraindication [1]. For people who have had angioedema or anaphylaxis with another GLP-1 receptor agonist, the label advises caution, because it is unknown whether they will be predisposed to the same reactions with tirzepatide [1].

Angioedema is deep swelling of the skin or mucous membranes, often of the face, lips or throat. The label names it, alongside anaphylaxis, as a serious hypersensitivity reaction reported with Mounjaro, and lists injection site reactions as a separate adverse reaction [1].

What the trials show about injection site and hypersensitivity reactions

In the label's pool of placebo-controlled adult trials, injection site reactions were reported in 3.2% of Mounjaro-treated patients versus 0.4% of placebo-treated patients, and hypersensitivity reactions in 3.2% versus 1.7% [1].

In an analysis of seven trials involving 5,025 adults with type 2 diabetes who could be evaluated for antibodies, treatment-emergent anti-tirzepatide antibodies developed in 51.1% of patients; neutralizing antibodies against tirzepatide activity at the GIP and GLP-1 receptors were found in 1.9% and 2.1% respectively [2]. Injection site or hypersensitivity reactions were more frequent among people who developed antibodies (for injection site reactions, 4.6% of antibody-positive versus 0.7% of antibody-negative adults in the label's seven-trial pool). Most reported reactions were nonserious and nonsevere, and most occurred or resolved regardless of antibody status or titer [1][2].

A 2026 systematic review included 24 phase 3 trials in adults with overweight or obesity, 23 of which were eligible for its network meta-analysis; tirzepatide was associated with a higher risk of injection site reactions, and there was no significant difference between tirzepatide, semaglutide and liraglutide for serious adverse events [3]. Those were weight-management trials; Mounjaro itself is labeled for type 2 diabetes in adults and children 10 and older, and for reducing cardiovascular risk in adults with type 2 diabetes [1].

What does the label say about injection technique?

The label says to inject subcutaneously in the abdomen, the thigh, or have another person inject into the back of the upper arm, and to rotate injection sites with each dose [1]. Doses are given once weekly, at any time of day, with or without meals [1]. The Mounjaro label says the solution should appear clear and colorless to slightly yellow, and says not to use it if particulate matter or discoloration is visible [1]. The KwikPen is not recommended for self-administration by pediatric patients or by people who are visually impaired, and a KwikPen must never be shared between patients, even with a new needle [1].